Company Profile
Gyre Therapeutics Stock Price, News & Analysis
- Ticker:
- GYRE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.40 USD (+2.73%)
Close
Last updated: August 6, 2026
539M USD
Market cap
Why the stock is moving
The latest monitored company update is “Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.
Company overview
Fibrosis and Inflammation Franchise
Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China. Its small-molecule portfolio is centered on organ fibrosis and inflammatory diseases.
Commercial Products in China
Gyre Pharmaceuticals commercializes ETUARY, a pirfenidone therapy for idiopathic pulmonary fibrosis, alongside Etorel for systemic sclerosis-associated interstitial lung disease and progressive pulmonary fibrosis and Contiva for thrombocytopenia.
F351 Liver-Fibrosis Program
F351, or hydronidone, is a modified derivative of pirfenidone that targets TGF-beta1 signaling. Its China NDA for chronic hepatitis B-associated liver fibrosis is under priority review, while U.S. development is directed toward MASH-associated liver fibrosis.
Expanded Pirfenidone Development
The company is also evaluating pirfenidone in a Phase 3 pneumoconiosis study and an adaptive Phase 2/3 study of radiation-induced lung injury and other oncology-related pulmonary complications in China.
Targeted Protein Degradation
Through its acquisition of Cullgen, Gyre added targeted protein degraders and degrader-antibody conjugates for cancer and inflammatory disease. The acquired portfolio includes clinical programs in cancer pain, solid tumors and hematologic malignancies, plus IND-enabling dual degraders.
Future catalysts
Final-patient completion in the China Phase 3 study of pirfenidone for pneumoconiosis by the fourth quarter of 2026.
U.S. and/or China IND submissions for the CG923308 CDK2-Cyclin E dual degrader and CG620953 TYK2-JAK1 dual degrader in the first quarter of 2027.
Recent news
- 01
- 02
Gyre Therapeutics Appoints Three New Members to its Board of Directors
Source: Gyre Therapeutics
- 03
- 04
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Source: Gyre Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Gyre Therapeutics (GYRE)?
Gyre Therapeutics (GYRE) most recently closed at 6.40 USD, a +2.73% move versus the previous session.
What is the market cap of Gyre Therapeutics (GYRE)?
Gyre Therapeutics currently has a market capitalization of 539M USD on BioPharmSignal.
What does Gyre Therapeutics do?
Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China. Its small-molecule portfolio is centered on organ fibrosis and inflammatory diseases. Commercial Products in China Gyre Pharmaceuticals commercializes ETUARY, a pirfenidone therapy for idiopathic pulmonary fibrosis,...
On which exchange is GYRE stock listed?
Gyre Therapeutics (GYRE) is associated with NASDAQ, United States, Biopharma.
What is Fibrosis?
Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China.
Which conditions is Gyre Therapeutics targeting with Fibrosis?
Gyre Therapeutics is associated with oncology, cancer therapeutics, inflammatory disease based on its company overview and current catalyst commentary.
How does Gyre Therapeutics describe recent progress with Fibrosis?
Final-patient completion in the China Phase 3 study of pirfenidone for pneumoconiosis by the fourth quarter of 2026. U.S. and/or China IND submissions for the CG923308 CDK2-Cyclin E dual degrader and CG620953 TYK2-JAK1 dual degrader in the first quarter of 2027.
What is Inflammation?
Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China.